Association of endocan expression with clinicopathological prognostic parameters in breast carcinoma

Article type: Research Article

Authors: Celik, Zeliha Esin^{a; *} | Demir, Fatih^a | Yonar, Harun^b | Ugras, Serdar^a

Affiliations: [a] Pathology Department, Faculty of Medicine, Selcuk University, Konya, Turkey | [b] Department of Biostatistics, Faculty of Veterinary Medicine, Selcuk University, Konya, Turkey

Correspondence: [*] Corresponding author: Zeliha Esin Celik, Pathology Department, Faculty of Medicine, Selcuk University, 42130, Selcuklu, Konya, Turkey. %****␣cbm-32-cbm201026_temp.tex␣Line␣25␣**** Tel.: +90 533 661 1633; E-mail: esincelik@selcuk.edu.tr.

Abstract: BACKGROUND: Breast cancer (BC) is a common malignancy in women. Some molecules, including endocan, are still under investigation as potential prognostic factors in BC. OBJECTIVE: In the present study, we aimed to determine the relationship between endocan expression and clinicopathological prognostic parameters in BC. METHODS: Two hundred and fifty-five patients diagnosed with BC were included in the present study. The immuno-reactivity scoring (IRS) system was used to reveal the tissue endocan expression levels. RESULTS: We found that endocan expression is associated with tumor necrosis, tumor size, and the presence of lobular carcinoma in situ (LCIS) in BC. There was no relationship between endocan expression and survival as well as other clinicopathological prognostic parameters. CONCLUSION: Endocan overexpression in BC is associated with some prognostic parameters, including tumor necrosis, tumor size, and the presence of LCIS. Further studies with larger series are needed to reveal the clinical and therapeutic implications of endocan in BC.

Keywords: Breast cancer, pathology, Endocan, immunohistochemistry, prognosis

DOI: 10.3233/CBM-201026

Journal: Cancer Biomarkers, vol. 32, no. 4, pp. 471-477, 2021